Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Flack

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
American Journal of Hypertension|June 24, 2016
Do We Need a New Definition of Hypertension After SPRINT?Ernesto L Schiffrin, David A Calhoun, John M Flack
American Journal of Hypertension|November 9, 2018
Resistant Hypertension: An UpdateDavid A Calhoun, Ernesto L Schiffrin, John M Flack
Evidence-Based Medicine|August 23, 2011
Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapyJohn M Flack, Samar A Nasser, Phillip D Levy
American Journal of Hypertension|November 25, 2015
SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a PriceErnesto L Schiffrin, David A Calhoun, John M Flack
Western Journal of Nursing Research|October 24, 2006
African American culture and hypertension preventionRosalind M Peters, Karen J Aroian, John M Flack
Hypertension (Dallas, Tex. : 1979)|April 15, 2026
Controversies, Challenges, and Dilemmas in Primary AldosteronismJohn M Flack, Adina F Turcu, Jordana B Cohen
Journal of Clinical Hypertension (Greenwich, Conn.)|January 31, 2003
Epidemiology of hypertension and cardiovascular disease in African AmericansJohn M Flack, Kieth C Ferdinand, Samar A Nasser
Current Hypertension Reports|February 16, 2024
Resistant Hypertension: Disease Burden and Emerging Treatment OptionsJohn M Flack, Michael G Buhnerkempe, Kenneth Todd Moore
Postgraduate Medicine|June 14, 2012
Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertensionJohn M Flack, Alan Graff, Wei Li, et al.
Plos One|January 5, 2012
A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysisBrian A Ference, Wonsuk Yoo, John M Flack, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
American Journal of Hypertension|June 24, 2016
Do We Need a New Definition of Hypertension After SPRINT?Ernesto L Schiffrin, David A Calhoun, John M Flack
American Journal of Hypertension|November 9, 2018
Resistant Hypertension: An UpdateDavid A Calhoun, Ernesto L Schiffrin, John M Flack
Evidence-Based Medicine|August 23, 2011
Initial treatment of hypertension with aliskiren and amlodipine combination gives 6.5 mm Hg greater reduction in systolic BP than does either monotherapyJohn M Flack, Samar A Nasser, Phillip D Levy
American Journal of Hypertension|November 25, 2015
SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a PriceErnesto L Schiffrin, David A Calhoun, John M Flack
Western Journal of Nursing Research|October 24, 2006
African American culture and hypertension preventionRosalind M Peters, Karen J Aroian, John M Flack
Hypertension (Dallas, Tex. : 1979)|April 15, 2026
Controversies, Challenges, and Dilemmas in Primary AldosteronismJohn M Flack, Adina F Turcu, Jordana B Cohen
Journal of Clinical Hypertension (Greenwich, Conn.)|January 31, 2003
Epidemiology of hypertension and cardiovascular disease in African AmericansJohn M Flack, Kieth C Ferdinand, Samar A Nasser
Current Hypertension Reports|February 16, 2024
Resistant Hypertension: Disease Burden and Emerging Treatment OptionsJohn M Flack, Michael G Buhnerkempe, Kenneth Todd Moore
Postgraduate Medicine|June 14, 2012
Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertensionJohn M Flack, Alan Graff, Wei Li, et al.
Plos One|January 5, 2012
A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: two meta-analyses and a meta-regression analysisBrian A Ference, Wonsuk Yoo, John M Flack, et al.
Pageof 16